China CRO stocks extend decline; Lianya plunges over 20%, WuXi AppTec drops 5%

The breadth of the move matters more than any single name: a double-digit drop in one CRO alongside declines across WuXi AppTec, Medicilon, Pharmaron and Joinn points to sector-level repricing rather than company-specific news. That the selling extends an existing decline suggests sentiment toward the contract research complex remains fragile, with the smaller, less diversified names absorbing the sharpest moves. Whether the weakness broadens further into the larger-cap leaders or stabilizes around current levels is the open question worth watching.